Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Amca
2. Amcha
3. Amchafibrin
4. Anvitoff
5. Cyklokapron
6. Exacyl
7. Kabi 2161
8. Spotof
9. T-amcha
10. Trans-4-(aminomethyl)cyclohexanecarboxylic Acid
11. Transamin
12. Ugurol
1. 1197-18-8
2. Trans-4-(aminomethyl)cyclohexanecarboxylic Acid
3. Cyklokapron
4. 4-(aminomethyl)cyclohexanecarboxylic Acid
5. Trans Amcha
6. Tranexamsaeure
7. Transamin
8. 701-54-2
9. Tranhexamic Acid
10. Cyclocapron
11. Amstat
12. Trans-amcha
13. 1197-17-7
14. Rikavarin
15. Tamcha
16. Amikapron
17. Anvitoff
18. Ugurol
19. Amcha
20. Frenolyse
21. Trasamlon
22. Carxamin
23. Emorhalt
24. Tranexan
25. Mastop
26. Rikavarin-s
27. Amca
28. Cis-4-(aminomethyl)cyclohexanecarboxylic Acid
29. Exacyl
30. Tranexmic Acid
31. Hexapromin
32. Transamlon
33. Hexatron
34. Spiramin
35. Tranex
36. Cis-amcha
37. Cis-tranexamic Acid
38. Trans-4-aminomethylcyclohexane-1-carboxylic Acid
39. 4-(aminomethyl)cyclohexane-1-carboxylic Acid
40. Trans-tranexamic Acid
41. Acidum Tranexamicum
42. Cyclohexanecarboxylic Acid, 4-(aminomethyl)-, Trans-
43. Lysteda
44. Acido Tranexamico
45. Cl 65336
46. Acide Tranexamique
47. Femstrual
48. Bay 3517
49. Cyclo-f
50. Rp 18,429
51. Cyclohexanecarboxylic Acid, 4-(aminomethyl)-
52. 4-(aminomethyl)-cyclohexanecarboxylic Acid
53. Cyclohexanecarboxylic Acid, 4-(aminomethyl)-, Cis-
54. Cyclokapron
55. Espercil
56. Haematrix
57. (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic Acid
58. Cis-4-aminomethylcyclohexane-1-carboxylic Acid
59. Trans-p-(aminomethyl)cyclohexanecarboxylic Acid
60. Cl-65336
61. Dv 79
62. Dv79
63. Trans-4-(aminomethyl)-1-cyclohexanecarboxylic Acid
64. Lb1148
65. Mfcd00001466
66. Cis-4-(aminomethyl)cyclohexane-1-carboxylic Acid
67. Nsc-291305
68. Trans-1-(aminomethyl)cyclohexane-4-carboxylic Acid
69. Trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid
70. Tranexamic Acid (transamin)
71. Retavase
72. Chebi:48669
73. 37yd696ii6
74. 6t84r30kc1
75. Nsc291305
76. Trans-4-(aminomethyl)cyclohexanecarboxylic Acid Ester
77. 4-aminomethylcyclohexanecarboxylic Acid
78. Ncgc00016569-01
79. Rp-18429
80. Cas-1197-18-8
81. 4-(aminomethyl)cyclohexanecarboxylic Acid (trans-)
82. Amh
83. Tranexamic Acid Cis-form
84. Acide Tranexamique [inn-french]
85. Acido Tranexamico [inn-spanish]
86. Acidum Tranexamicum [inn-latin]
87. Dv-79
88. Cyklokapron (tn)
89. Rikavarin (tn)
90. Transamin (tn)
91. Haku
92. Sr-05000001794
93. Einecs 214-818-2
94. Trans-1-aminomethylcyclohexane-4-carboxylic Acid
95. Nsc 291305
96. Brn 2207452
97. Tranexamate
98. Tranexamic-acid
99. Unii-37yd696ii6
100. Unii-6t84r30kc1
101. 1ceb
102. Prestwick_476
103. Albb-006013
104. Tranexamic Acid,(s)
105. Spectrum_001391
106. Tranexamic Acid [usan:usp:inn:ban:jan]
107. Prestwick0_000171
108. Prestwick1_000171
109. Prestwick2_000171
110. Prestwick3_000171
111. Spectrum2_000655
112. Spectrum3_001189
113. Spectrum4_000046
114. Spectrum5_001258
115. Chembl877
116. Trans-4-(aminomethyl)cyclohexane-carboxylic Acid
117. Dsstox_cid_25350
118. Dsstox_rid_80817
119. Dsstox_gsid_45350
120. Oprea1_786414
121. Schembl16974
122. Bspbio_000061
123. Bspbio_002837
124. Kbiogr_000511
125. Kbioss_001871
126. Tranexamic Acid [mi]
127. 3-14-00-00868 (beilstein Handbook Reference)
128. Cis-4-(aminomethyl)cyclohexanecarboxylicacid
129. Divk1c_000655
130. Schembl186034
131. Schembl349408
132. Spectrum1502026
133. Tranexamic Acid [inn]
134. Tranexamic Acid [jan]
135. Tranexamic Acid, Cis-
136. Spbio_000689
137. Spbio_001982
138. Tranexamic Acid [inci]
139. Tranexamic Acid [usan]
140. Bpbio1_000069
141. Chembl292500
142. Gtpl6573
143. Schembl6885575
144. Schembl9885628
145. Tranexamic Acid [vandf]
146. Dtxsid3045350
147. Tranexamic Acid [mart.]
148. Chebi:94518
149. Hms502a17
150. Kbio1_000655
151. Kbio2_001871
152. Kbio2_004439
153. Kbio2_007007
154. Kbio3_002337
155. Dtxsid50904827
156. Tranexamic Acid [usp-rs]
157. Tranexamic Acid [who-dd]
158. Wln: L6tj Avq D1z -t
159. Ninds_000655
160. Hms1568d03
161. Hms1921f08
162. Hms2092p03
163. Hms2095d03
164. Hms3712d03
165. Hms3744g07
166. Pharmakon1600-01502026
167. Bcp13133
168. Bcp18146
169. Hy-b0149
170. Tranexamic Acid (jp17/usp/inn)
171. Zinc1542907
172. Tox21_110500
173. Bbl004469
174. Bdbm50428067
175. Ccg-39692
176. Mfcd00064951
177. Mfcd19706018
178. Nsc758176
179. S1875
180. Stk503668
181. Tranexamic Acid [orange Book]
182. Tranexamic Acid(random Configuration)
183. Akos005171632
184. Akos015854573
185. Akos024257901
186. Tranexamic Acid [ep Monograph]
187. Tranexamic Acid [usp Impurity]
188. Tranexamic Acid Cis-form [mi]
189. Zinc100007011
190. Zinc100071256
191. Ab86495
192. Ac-4687
193. Am84352
194. Bs-3867
195. Cs-1965
196. Db00302
197. Nsc-758176
198. Tranexamic Acid [usp Monograph]
199. 4-(aminomethyl)cyclohexanecarboxylicacid
200. 4-aminomethyl-cyclohexanecarboxylic Acid
201. Idi1_000655
202. Ncgc00016569-02
203. Ncgc00016569-03
204. Ncgc00016569-04
205. Ncgc00016569-05
206. Ncgc00016569-06
207. Ncgc00016569-08
208. Ncgc00016569-09
209. Ncgc00094944-01
210. Ncgc00094944-02
211. P-(aminomethyl)cyclohexanecarboxylic Acid
212. As-80121
213. Bp-12345
214. Sy011438
215. Tranexamic Acid Related Compound B
216. Ts-02090
217. Sbi-0051705.p002
218. Trans 4aminomethylcyclohexanecarboxylic Acid
219. Db-074265
220. Tranexamic Acid 100 Microg/ml In Methanol
221. Trans-4-aminomethylcyclohexylcarboxylic Acid
222. Trans-p-aminomethylcyclohexanecarboxylic Acid
223. A0236
224. Ab00052260
225. Bb 0260034
226. Cs-0013687
227. Cs-0055045
228. Ft-0654339
229. Ft-0675360
230. Ft-0700806
231. Trans 4-aminomethylcyclohexanecarboxylic Acid
232. Trans-4-aminomethylcyclohexanecarboxylic Acid
233. En300-91506
234. Trans-4(aminomethyl)cyclohexanecarboxylic Acid
235. Trans-4-(aminomethyl)cyclohexylcarboxylic Acid
236. Trans-4-aminomethyl Cyclohexanecarboxylic Acid
237. Trans-4-aminomethyl-cyclohexanecarboxylic Acid
238. Trans-4-aminomethylcyclohexane Carboxylic Acid
239. D01136
240. P15619
241. P20836
242. T71247
243. Trans-4-aminomethyl Cyclohexane Carboxylic Acid
244. Trans4-aminomethylcyclohexane-1-carboxylic Acid
245. Ab00052260-04
246. Ab00052260_05
247. Ab00052260_06
248. Tranexamic Acid Impurity B [ep Impurity]
249. Trans-4 -(aminomethyl)cyclohexanecarboxylic Acid
250. Trans-4-(aminomethyl)-cyclohexanecarboxylic Acid
251. Trans-4-(aminomethyl)cyclohexane Carboxylic Acid
252. Trans-4-aminomethyl-1-cyclohexanecarboxylic Acid
253. (1r,4r)-4-(aminomethyl)cyclohexanecarboxylic Acid
254. (trans)-4-(aminomethyl)cyclohexanecarboxylic Acid
255. 197t188
256. 4-trans-(aminomethyl)cyclohexanecarboxylic Acid #
257. Q418666
258. Trans-?4-?(aminomethyl)?cyclohexanecarboxylic Acid
259. Trans-4- (aminomethyl) Cyclohexanecarboxylic Acid
260. Trans-4-(aminomethyl)- Cyclohexane Carboxylic Acid
261. Trans-4-(aminomethyl)-cyclohexane Carboxylic Acid
262. Trans-4-aminomethyl-1-cyclohexane Carboxylic Acid
263. 4alpha-aminomethyl-1alpha-cyclohexanecarboxylic Acid
264. Q-201848
265. Sr-05000001794-1
266. Sr-05000001794-2
267. Sr-05000001794-3
268. Tranexamic Acid 100 Microg/ml In Acetonitrile:water
269. Brd-k15014948-001-01-2
270. Q27256710
271. Trans-4-(aminomethyl)cyclohexanecarboxylic Acid, 97%
272. 4-(aminomethyl)cyclohexanecarboxylic Acid;tranexamic Acid
273. F8886-7867
274. Tranexamic Acid Related Compound B [usp Impurity]
275. Z1741970429
276. Rel-(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic Acid
277. Tranexamic Acid, European Pharmacopoeia (ep) Reference Standard
278. 4-(aminomethyl)cyclohexanecarboxylic Acid (cis- And Trans- Mixture)
279. Tranexamic Acid, United States Pharmacopeia (usp) Reference Standard
280. 4-(aminomethyl)cyclohexanecarboxylic Acid (cis- And Trans- Mixture);
281. Tranexamic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 157.21 g/mol |
|---|---|
| Molecular Formula | C8H15NO2 |
| XLogP3 | -2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 157.110278721 g/mol |
| Monoisotopic Mass | 157.110278721 g/mol |
| Topological Polar Surface Area | 63.3 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 139 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Cyklokapron |
| PubMed Health | Tranexamic Acid |
| Drug Classes | Hemostatic |
| Drug Label | Each mL of the sterile solution for intravenous injection contains 100 mg tranexamic acid and Water for Injection to 1 mL.... |
| Active Ingredient | Tranexamic acid |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 100mg/ml |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 6 | |
|---|---|
| Drug Name | Lysteda |
| PubMed Health | Tranexamic Acid |
| Drug Classes | Hemostatic |
| Drug Label | LYSTEDA is an antifibrinolytic drug. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:Tranexamic acid is a white crystalline... |
| Active Ingredient | Tranexamic acid |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 650mg |
| Market Status | Prescription |
| Company | Ferring Pharms As |
| 3 of 6 | |
|---|---|
| Drug Name | Tranexamic acid |
| PubMed Health | Tranexamic Acid |
| Drug Classes | Hemostatic |
| Drug Label | Tranexamic Acid Tablets is an antifibrinolytic drug. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic aci... |
| Active Ingredient | Tranexamic acid |
| Dosage Form | Tablet; Injectable |
| Route | Injection; Oral |
| Strength | 650mg; 650 mg; 100mg/ml |
| Market Status | Prescription |
| Company | Actavis Labs Fl; Apotex; Acic Fine Chems; Emcure Pharms; Fresenius Kabi Usa; Versapharm; Mylan Institutional; X-gen Pharms; Luitpold |
| 4 of 6 | |
|---|---|
| Drug Name | Cyklokapron |
| PubMed Health | Tranexamic Acid |
| Drug Classes | Hemostatic |
| Drug Label | Each mL of the sterile solution for intravenous injection contains 100 mg tranexamic acid and Water for Injection to 1 mL.... |
| Active Ingredient | Tranexamic acid |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 100mg/ml |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 5 of 6 | |
|---|---|
| Drug Name | Lysteda |
| PubMed Health | Tranexamic Acid |
| Drug Classes | Hemostatic |
| Drug Label | LYSTEDA is an antifibrinolytic drug. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:Tranexamic acid is a white crystalline... |
| Active Ingredient | Tranexamic acid |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 650mg |
| Market Status | Prescription |
| Company | Ferring Pharms As |
| 6 of 6 | |
|---|---|
| Drug Name | Tranexamic acid |
| PubMed Health | Tranexamic Acid |
| Drug Classes | Hemostatic |
| Drug Label | Tranexamic Acid Tablets is an antifibrinolytic drug. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic aci... |
| Active Ingredient | Tranexamic acid |
| Dosage Form | Tablet; Injectable |
| Route | Injection; Oral |
| Strength | 650mg; 650 mg; 100mg/ml |
| Market Status | Prescription |
| Company | Actavis Labs Fl; Apotex; Acic Fine Chems; Emcure Pharms; Fresenius Kabi Usa; Versapharm; Mylan Institutional; X-gen Pharms; Luitpold |
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. At much higher concentrations it behaves as a noncompetitive inhibitor of plasmin similar to [aminocaproic acid], a similar antifibrinolytic which is 10-fold less potent. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1). Off-target antagonism of GABA(A) receptors may be associated with the development of convulsions and hyperexcitability following tranexamic acid administration - the risk appears higher with improper administration or administration during cardiovascular surgery. Consider EEG monitoring of patients with a history of seizure.
Antifibrinolytic Agents
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. (See all compounds classified as Antifibrinolytic Agents.)
B02AA02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
B - Blood and blood forming organs
B02 - Antihemorrhagics
B02A - Antifibrinolytics
B02AA - Amino acids
B02AA02 - Tranexamic acid
Absorption
The bioavailability of tranexamic acid after oral administration in humans is approximately 30 to 50% of the ingested dose and is not affected by food intake. The Cmax and Tmax following multiple oral doses (1300 mg three times daily x 5 days) were 16.41 mcg/mL and 2.5 h, respectively.
Route of Elimination
Urinary excretion is the primary means of tranexamic acid elimination, with >95% of an administered dose excreted in the urine as unchanged parent drug. The rate of excretion is dependent on the route of administration - approximately 90% of an intravenously administered dose is excreted within 24 hours whereas only 39% of an orally administered dose is excreted within the same time frame.
Volume of Distribution
The initial volume of distribution of tranexamic acid is 0.18 L/kg and its steady-state volume of distribution is 0.39 L/kg. Tranexamic acid distributes into cerebrospinal fluid and the aqueous humor of the eye at concentrations approximately 1/10th of typical plasma concentrations. Tranexamic acid is also able to cross the placenta, found in cord blood at concentrations equivalent to maternal plasma concentrations.
Clearance
The plasma clearance of tranexamic acid is 110-116 mL/min.
Tranexamic acid metabolism is poorly characterized but does not appear to be a significant means of drug elimination. According to prescribing information, approximately 1% and 0.5% of an orally administered dose are excreted as a dicarboxylic acid and acetylated metabolite, respectively.
Following intravenous administration, the apparent elimination half-life is approximately 2 hours and the mean terminal half-life is approximately 11 hours.
Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage.
API SUPPLIERS
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37130
Submission : 2022-07-29
Status : Active
Type : II
Certificate Number : CEP 2022-243 - Rev 00
Issue Date : 2024-09-13
Type : Chemical
Substance Number : 875
Status : Valid
Date of Issue : 2022-06-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0093
Address of the Firm :
NDC Package Code : 57218-951
Start Marketing Date : 2020-12-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
AMI Lifesciences is Driven by Chemistry. Powered by People.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-13
Pay. Date : 2023-11-01
DMF Number : 36336
Submission : 2021-10-07
Status : Active
Type : II
Certificate Number : R0-CEP 2019-250 - Rev 02
Issue Date : 2022-04-04
Type : Chemical
Substance Number : 875
Status : Valid
Date of Issue : 2022-08-11
Valid Till : 2025-06-26
Written Confirmation Number : WC-0054
Address of the Firm :
NDC Package Code : 59680-012
Start Marketing Date : 2023-07-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : MX, CN |
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Lifecare Labs has been developing innovative products in specialist areas of medicine.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-04
Pay. Date : 2018-09-04
DMF Number : 33086
Submission : 2018-09-05
Status : Active
Type : II
Certificate Number : CEP 2018-048 - Rev 02
Issue Date : 2024-10-21
Type : Chemical
Substance Number : 875
Status : Valid
Date of Issue : 2019-07-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0147
Address of the Firm :
NDC Package Code : 82920-038
Start Marketing Date : 2022-08-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Registrant Name : Palm East Co., Ltd.
Registration Date : 2022-09-05
Registration Number : 20210325-210-J-831(1)
Manufacturer Name : Shilpa Pharma Lifesciences Limited (unit-2)
Manufacturer Address : Plot No. 33, 33A, 40 to 47, Block C,D,E,H,I & AM, Raichur Industrial Growth Centre, Chicksugur - 584 134 Dist: Raichur. Karnataka India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37130
Submission : 2022-07-29
Status : Active
Type : II
AMI Lifesciences is Driven by Chemistry. Powered by People.
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-11-01
DMF Number : 36336
Submission : 2021-10-07
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-31
Pay. Date : 2013-01-04
DMF Number : 22277
Submission : 2008-12-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-12-20
Pay. Date : 2018-12-11
DMF Number : 25331
Submission : 2011-09-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9418
Submission : 1991-11-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3864
Submission : 1980-07-10
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-11
Pay. Date : 2012-12-07
DMF Number : 14181
Submission : 1999-05-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-05-27
Pay. Date : 2016-05-23
DMF Number : 26128
Submission : 2012-06-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15119
Submission : 2000-11-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4856
Submission : 1983-02-17
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Certificate Number : CEP 2022-243 - Rev 00
Status : Valid
Issue Date : 2024-09-13
Type : Chemical
Substance Number : 875
AMI Lifesciences is Driven by Chemistry. Powered by People.
AMI Lifesciences is Driven by Chemistry. Powered by People.
Certificate Number : R0-CEP 2019-250 - Rev 02
Status : Valid
Issue Date : 2022-04-04
Type : Chemical
Substance Number : 875
Certificate Number : R1-CEP 2008-186 - Rev 01
Status : Valid
Issue Date : 2020-05-05
Type : Chemical
Substance Number : 875
Certificate Number : R0-CEP 2009-109 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2011-10-07
Type : Chemical
Substance Number : 875
Certificate Number : R1-CEP 1998-027 - Rev 03
Status : Withdrawn by Holder
Issue Date : 2010-03-04
Type : Chemical
Substance Number : 875
Certificate Number : R1-CEP 2006-142 - Rev 03
Status : Valid
Issue Date : 2023-06-08
Type : Chemical
Substance Number : 875
Certificate Number : R1-CEP 2012-271 - Rev 02
Status : Valid
Issue Date : 2022-09-14
Type : Chemical
Substance Number : 875
Certificate Number : CEP 2018-048 - Rev 02
Status : Valid
Issue Date : 2024-10-21
Type : Chemical
Substance Number : 875
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
NDC Package Code : 57218-951
Start Marketing Date : 2020-12-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
AMI Lifesciences is Driven by Chemistry. Powered by People.
NDC Package Code : 59680-012
Start Marketing Date : 2023-07-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12848-1004
Start Marketing Date : 1972-04-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 47554-001
Start Marketing Date : 2011-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71052-166
Start Marketing Date : 2020-05-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10000g/10000g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12079-2001
Start Marketing Date : 2011-10-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62991-3131
Start Marketing Date : 2017-10-17
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 38779-3211
Start Marketing Date : 2020-02-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-0022
Start Marketing Date : 2014-06-06
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 82920-045
Start Marketing Date : 2023-05-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Cyklokapron-Generic (tranexamic acid) is a plasminogen inhibitor, small molecule drug candidate. which is indicated for the treatment of patients with hemophilia.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Genetic Disease Brand Name: Cyklokapron-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Tranexamic Acid Injection, USP in the U.S. Market
Details : Cyklokapron-Generic (tranexamic acid) is a plasminogen inhibitor, small molecule drug candidate. which is indicated for the treatment of patients with hemophilia.
Brand Name : Cyklokapron-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2024
Details:
Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Dental and Oral Health Brand Name: Tranexamic Acid Oral Rinse
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Enrolls First Patient in Phase 3 for Proprietary Mouth Rinse for Dental Bleeding
Details : Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Brand Name : Tranexamic Acid Oral Rinse
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: LB1148
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bow...
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 09, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Details : LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bow...
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2023
Details:
LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palisade Bio LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
Details : LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bo...
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2023
Details:
LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
Details : LB1148 (tranexamic acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bo...
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2023
Details:
LB1148 (tranexamic Acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
Details : LB1148 (tranexamic Acid), is a broad-spectrum serine protease inhibitor that has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bo...
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2023
Details:
LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. It is being investigated to accelerate the return of bowel function following abdominal surgery.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Newsoara Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Newsoara Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LB1148 (tranexamic acid) is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. It is being investigated to accelerate the return of bowel function following abdominal surgery.
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2023
Details:
In clinical studies, LB1148 (tranexamic acid) has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In clinical studies, LB1148 (tranexamic acid) has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function.
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 16, 2022
Details:
The oral presentation will include new GI functional data sub-cuts from highly statistically significant Phase 2 clinical study demonstrating LB1148 (tranexamic acid) accelerated the return of post-operative GI function in patients undergoing elective bowel resection.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Gastroenterology Brand Name: LB1148
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The oral presentation will include new GI functional data sub-cuts from highly statistically significant Phase 2 clinical study demonstrating LB1148 (tranexamic acid) accelerated the return of post-operative GI function in patients undergoing elective bo...
Brand Name : LB1148
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 100MG/ML
USFDA APPLICATION NUMBER - 19281
DOSAGE - TABLET;ORAL - 650MG
USFDA APPLICATION NUMBER - 22430
Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Huzhou Sunflower Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : It is used as an adhesive agent.
Pharmacopoeia Ref : Not Available
Technical Specs : Also Available as AnyCoat®-C AN3, AN4, AN5, AN6, AN15, AN50, BN4
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : It is used as a filler in formulation.
Pharmacopoeia Ref : Not Available
Technical Specs : Also Available as Comprecel M102, M102CG, M103, M105, M124, M113, M200, M224, M301, M302
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Capsule
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : It is used as a disintegrating agent.
Pharmacopoeia Ref : Not Available
Technical Specs : Also Available as Disolcel® GF
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : It is used as a lubricant.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : It is used as a filler in formulation.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Controlled & Modified Release
Disintegrants & Superdisintegrants
Granulation
Film Formers & Plasticizers
Thickeners and Stabilizers
Lubricants & Glidants
Co-Processed Excipients
Solubilizers
Taste Masking
Topical
Chewable & Orodispersible Aids
Parenteral
Empty Capsules
Vegetarian Capsules
API Stability Enhancers
Emulsifying Agents
Rheology Modifiers
Coloring Agents
Surfactant & Foaming Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
FDF DOSSIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
